These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31248688)

  • 41. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan.
    Ozawa N; Ito K; Tase T; Shibuya D; Metoki H; Yaegashi N
    Tohoku J Exp Med; 2017 Dec; 243(4):329-334. PubMed ID: 29269635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
    Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
    Falcaro M; Soldan K; Ndlela B; Sasieni P
    BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prevalence of HPV associated cervical intraepithelial neoplasia in women under age 21: who will be missed under the new cervical cancer screening guidelines?
    DeCew AE; Hadler JL; Daley AM; Niccolai L
    J Pediatr Adolesc Gynecol; 2013 Dec; 26(6):346-9. PubMed ID: 24119656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
    Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
    Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
    Verdoodt F; Dehlendorff C; Kjaer SK
    Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.
    Kang YJ; Lewis H; Smith MA; Simonella L; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2015 Aug; 15():365. PubMed ID: 26297490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study.
    Rodriguez AM; Zeybek B; Vaughn M; Westra J; Kaul S; Montealegre JR; Lin YL; Kuo YF
    Cancer; 2020 Apr; 126(8):1656-1667. PubMed ID: 32037524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era.
    Oakley F; Desouki MM; Pemmaraju M; Gargano JM; Markowitz LE; Steinau M; Unger ER; Zhu Y; Fadare O; Griffin MR
    Am J Prev Med; 2018 Jul; 55(1):19-25. PubMed ID: 29778314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women.
    Innes CR; Williman JA; Simcock BJ; Hider P; Sage M; Dempster-Rivett K; Lawton BA; Sykes PH
    N Z Med J; 2020 Jan; 133(1508):72-84. PubMed ID: 31945044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
    Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
    Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fewer shots proposed to increase uptake of HPV vaccine.
    Dorans K
    Nat Med; 2010 Aug; 16(8):832-3. PubMed ID: 20689528
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26year old females.
    Hirth JM; Lin YL; Kuo YF; Berenson AB
    Prev Med; 2016 Jul; 88():134-9. PubMed ID: 27085993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving Cervical Precancer Surveillance: Validity of Claims-Based Prediction Models in ICD-9 and ICD-10 Eras.
    Shing JZ; Griffin MR; Nguyen LD; Slaughter JC; Mitchel EF; Pemmaraju M; Rentuza AB; Hull PC
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.